Conference Day 2 | Thursday December 14, 2023

8:30 am Morning Welcome Coffee

9:00 am Chair’s Opening Remarks

Optimizing Systemic & Cell-Based Delivery to Achieve Effective Oncolytic Virotherapies for Patients

9:30 am Optimized Cell-Based Delivery & Potentiation of Oncolytic Virotherapies

  • Boris Minev President, Medical & Scientific Affairs, Calidi Biotherapeutics Inc.

Synopsis

  • The novel Calidi’s platform leverages allogeneic stem cells, combined with an oncolytic virus payload, which prevents the viral elimination by the patient’s immune system, and facilitates initial viral amplification and expansion at the tumor sites
  • Calidi’s final product contains not only stem cells loaded with viral particles, but also immune modulatory cytokines produced by the stem cells as well as virally encoded proteins (natural or engineered). Therefore, the tumor microenvironment (TME) is modified immediately upon intratumoral injection to support effective viral amplification, oncolysis and immune modulation
  • Pre-clinical and initial clinical data in multiple tumor types have demonstrated potent anti-tumor effects of Calidi’s approach not only at the injected tumor site, but also at distant metastatic tumor sites. Importantly, there are significant, clinically documented synergistic effects of this approach with checkpoint inhibition

10:00 am enLIGHTEN™ the Spark in Cancer: Viral Immunotherapies Mark New Frontier

Synopsis

  • To create novel viral immunotherapies to modulate the tumor microenvironment by design
  • Utilizes artificial intelligence-guided methods to break down the complexity of the tumor microenvironment, identify druggable properties that correlate with clinical outcomes, and make in silico predictions for the best payload combinations for specific indications
  • Rational selection of a viral chassis from our suite of HSV-1 vectors allows enLIGHTEN™ to exploit tunable vector features and combine, in a single therapeutic, a multimodal, programmable tumor treatment

10:30 am Triplet Therapy to Combat Pancreatic Cancer

Synopsis

  • Pancreatic cancer has high stroma and myeloid cell content and has a dismal prognosis
  • LOAd703 is an adenovirus-based therapy encoding transgenes that target CD40 and 41BB in the tumor microenvironment (tumor and stroma) to generate anti-tumor immunity as well as replicating in cancer cells to cause oncolysis with release of antigens
  • LOAd703 is currently evaluated in combination with chemotherapy ± checkpoint blockade in patients with pancreatic cancer

11:00 am Morning Break & Networking

Uncover the Optimal Dosage Schedules for Your Promising Oncolytic Virus Candidate & Unearth the Next Groundbreaking Breakthrough for the Community

12:00 pm Panel Discussion: Uncovering the Future Landscape for Oncolytic Viruses & Debating the Roadmap Towards the Next Generation Beyond T-VEC

Synopsis

  • What innovative engineering strategies can be employed to enhance tumor targeting and therapeutic efficacy?
  • How can we optimize the design and sequencing of combination regimens for maximum efficacy?
  • What strategies or technologies hold promise for improving the durability of response in patients?
  • How can collaboration between academia, industry, and regulatory bodies be fostered to accelerate progress in the field?

1:00 pm Adenovirus Process Development & Clinical Trial Manufacture

Synopsis

• The critical steps in adenovirus process development – challenges and considerations involved in manufacturing

• Biovian’s approach for optimizing adenovirus production processes, showcasing successful case studies and lessons learned along the 20 years of operation

• GeneCity manufacturing facility expansion and seamless one-stop solution for adenovirus manufacturing

1:15 pm Networking Lunch

Navigating the Current Clinical Trial Landscape to Uncover The Potential Future for Oncolytic Virotherapies

2:15 pm A Landscape Analysis of Oncolytic Viruses

Synopsis

  • An overview of the current oncolytic virotherapy drug and trial landscapes
  • Trends within the space, including genetic modifications and combination approaches
  • An analysis of the preclinical landscape, and what it can tell us about the potential future of OVs

2:45 pm Afternoon Break & Networking

Unveiling the Thrilling Frontier of Next Generation Oncolytic Virotherapy Approaches to Supercharge Patient Response

3:45 pm Gene Edited & Engineered Stem Cell-Oncolytic Virus Platform Drives Immunotherapy for Metastatic Cancers

  • Khalid Shah Vice Chairman, Brigham & Women's Hospital at Harvard Medical School

Synopsis

  • Gene editing and engineering techniques have been combined with stem cell and oncolytic virus technology to develop a powerful platform for immunotherapy in metastatic cancers
  • The platform utilizes gene editing tools, such as CRISPR-Cas9, to modify stem cells and oncolytic viruses with specific anti-cancer properties
  • Stem cells, with their ability to self-renew and differentiate into various cell types, act as delivery vehicles for the oncolytic viruses

4:15 pm Neural Stem Cell Based-Oncolytic Virotherapy for Treatment of Glioblastoma

  • Jana Portnow Professor, Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center

Synopsis

  • Human neural stem cells are inherently tumor-tropic and can be modified to deliver a therapeutic agent
  • Pre-clinical data show that neural stem cells can improve the distribution of an oncolytic virus by delivering it across normal brain tissue to multiple invasive tumor sites
  • Neural stem cells can also protect the oncolytic virus from neutralizing antibodies while en route to sites of tumor
  • A phase I study of multiple intracerebral doses of neural stem cells carrying a second generation conditionally replicative adenovirus is currently being conducted in patients with recurrent glioblastoma

4:45 pm PeptiCRAd – A Novel Cancer Immunotherapy Approach Targeting Multiple Tumour Antigens

  • Sari Pesonen Chief Scientific Officer, Valo Therapeutics Ltd.

Synopsis

  • PeptiCRAd is a cutting-edge cancer immunotherapy approach that targets multiple tumor antigens simultaneously
  • By targeting multiple tumor antigens, PeptiCRAd increases the likelihood of immune recognition and response against a wide range of cancer types
  • PeptiCRAd has the potential to be a highly effective and versatile cancer immunotherapy, with applications in various cancer types

5:15 pm End of the 8th Oncolytic Virotherapy Summit 2023